GLIOBLASTOMA MULTIFORME

This early-stage study tests whether combining a standard drug (bevacizumab) with a device that uses sound waves (NaviFUS) can safely treat recurrent glioblastoma, an aggressive brain cancer. Ten adults whose tumor has returned after standard therapy will receive the combination.…

This study tests the safety of a device called TheraSphere GBM for people whose glioblastoma brain tumor has come back. About 36 adults will receive the treatment to see if it is safe and technically possible. The goal is to find a new way to control the disease when standard tre…

This early-phase trial is testing whether combining a precise type of radiation (FSRT) with an immunotherapy drug (atezolizumab) can help people with a fast-growing brain tumor called glioblastoma. Twelve newly diagnosed patients will receive the combination for two weeks before …

This early-stage study tests whether a new treatment using specially engineered immune cells (CAR T-cells) is safe for people with glioblastoma, a fast-growing brain cancer that has come back. About 36 participants will receive the cells directly into the fluid around the brain. …

This study tests whether adding the drug ruxolitinib to standard treatment (radiation and temozolomide) helps people with newly diagnosed glioblastoma live longer. About 190 adults will be randomly assigned to receive either the standard treatment alone or standard treatment plus…

This study looks at the genetic makeup of brain tumors in children, teens, and young adults newly diagnosed with high-grade glioma. Researchers will use this information to see if patients qualify for future treatment studies that target their specific tumor type. No treatment is…

This study is collecting blood and urine samples from 200 adults with glioblastoma (a serious brain tumor) who are receiving radiation therapy. Researchers want to see if levels of two proteins, VEGF and MMP, can help predict whether the tumor will come back within one year. The …